drugset / Trial / NCT07449780
A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
Timeline
- Start
- 2026-03-31
- Primary completion
- 2027-11-17
- Completion
- 2028-02-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadonilimab | Monoclonal antibody | — | Subcutaneous |
| Background | Capecitabine | Small molecule | — | Oral |
| Background | Oxaliplatin | Small molecule | — | Intravenous |